Clozapine Augmented with Glutamate Modulators in Refractory Schizophrenia: A Review and Metaanalysis

Abstract

Clozapine is an efficacious antipsychotic drug for patients with treatment-resistant schizophrenia, but does not sufficiently improve these symptoms in a substantial proportion of this population. There is no convincing evidence for the efficacy of any clozapine augmentation strategy. New evidence suggests that glutamate receptors are a candidate target for therapeutic effects in schizophrenia. We present an overview of studies assessing the potential clinical utility of adding glutamatergic agents to clozapine. We conducted 3 metaanalyses of data on positive, negative and overall symptoms of schizophrenia, analysing results from 3 studies on clozapine augmentation with glycine, 6 studies on lamotrigine add-on therapy to clozapine and 4 studies on topiramate addition to clozapine.

Key words

schizophrenia - refractory disease - augmentation - clozapine - glutamate

• References

• 1 Howes OD, Egerton A, Allan V et al. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. Curr Pharm Des 2009; 15: 2550-2559
• 2 Agid O, Foussias G, Singh S et al. Where to position clozapine: re-examining the evidence. Can J Psychiatry 2010; 55: 677-684
• 3 Buckley P, Miller A, Olsen J et al. When symptoms persist: clozapine augmentation strategies. Schizophr Bull 2001; 27: 615-628
• 4 Chakos M, Lieberman J, Hoffman E et al. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 2001; 158: 518-526
• 5 Sommer IE, Begemann MJH, Temmerman A et al. Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophr Bull 2012; 38: 1003-1011
• 6 Veerman SRT, Schulte PFJ, Begemann MJH et al. Non-glutamatergic augmentation strategies to clozapine: a review and metaanalysis. Pharmacopsychiatry 2014; In press
• 7 Loonen AJM, Stahl SM. Functional psychopharmacology is the way to go in pharmacotherapy for psychiatric disorders. Acta Psychiatr Scand 2010; 122: 435-437
• 8 Gordon JA. Testing the glutamate hypothesis of schizophrenia. Nat Neurosci 2010; 13: 2-4
• 9 Yeun EY, Zhong P, Yan Z. Homeostatic regulation of glutamatergic transmission by dopamine D4 receptors. Proc Natl Acad Sci USA 2010; 107: 22308-22313
• 10 Tanahashi S, Yamamura S, Nakagawa M et al. Clozapine, but not haloperidol, enhances glial D-serine and L-glutamate release in rat frontal cortex and primary cultured astrocytes. Br J Pharmacol 2012; 165: 1543-1555
• 11 Veerman SRT, Schulte PFJ, Haan Lde. The glutamate hypothesis: a pathogenic pathway from which pharmacological interventions have emerged. Pharmacopsychiatry 2014; In press
• 12 Kremer I, Vass A, Gorelik I et al. Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. Biol Psychiatry 2004; 56: 441-446
• 13 Goff DC, Keefe R, Citrome L et al. Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials. J Clin Psychopharmacol 2007; 27: 582-589
• 14 Tiihonen J, Halonen P, Wahlbeck K et al. Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. J Clin Psychiatry 2005; 66: 1012-1015
• 15 Borenstein M, Hedges L, Higgins J et al. Comprehensive Meta Analysis Version 2. Engelwood. NJ: Biostat Inc; 2005
• 16 Hedges LV. Distribution theory for Glass’s estimator of effect size and related estimators. J Educ Statistics 1981; 6: 107-128
• 17 Tiihonen J, Hallikainen T, Ryynänen OP et al. Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biol Psychiatry 2003; 54: 1241-1248
• 18 Zoccali R, Muscatello MR, Bruno A et al. The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: a double-blind, placebo-controlled study. Schizophr Res 2007; 93: 109-116
• 19 Shadish WR, Haddock CK. Combining estimates of effect size. In Cooper H, Hedges LV. eds. The Handbook of Research Synthesis. New York, NY: Russell Sage Foundation; 1994: 261-281
• 20 Kelley GA, Kelly KS. Statistical models for meta-analysis: a brief tutorial. World J Methodol 2012; 26; 2: 27-32
• 21 Higgins JPT, Thompson SG, Deeks JJ et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560
• 22 Potkin SG, Jin Y, Bunney BG et al. Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. Am J Psychiatry 1999; 156: 145-147
• 23 Evins AE, Fitzgerald SM, Wine L et al. Placebo-controlled trial of glycine added to clozapine in schizophrenia. Am J Psychiatry 2000; 157: 826-828
• 24 Diaz P, Bhaskara S, Dursun SM et al. Double-blind, placebo-controlled, crossover trial of clozapine plus glycine in refractory schizophrenia: negative results. J Clin Psychopharmacol 2005; 25: 277-278
• 25 Tsai GE, Yang P, Chung LC et al. D-serine added to clozapine for the treatment of schizophrenia. Am J Psychiatry 1999; 156: 1822-1825
• 26 Goff DC, Henderson DC, Evins AE et al. A Placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia. Biol Psychiatry 1999; 45: 512-514
• 27 Goff DC, Leahy L, Berman I et al. A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J Clin Psychopharmacol 2001; 21: 484-487
• 28 Lane HY, Huang CL, Wu PL et al. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biol Psychiatry 2006; 60: 645-649
• 29 Vayısoğlu S, Anıl Yağcıoğlu AE, Yağcıoğlu S et al. Lamotrigine augmentation in patients with schizophrenia who show partial response to clozapine treatment. Schizophr Res 2013; 143: 207-214
• 30 Ginsberg DL. Lamotrigine effective for treatment-resistant schizophrenia. Prim Psychiatry 2004; 11: 20-24
• 31 Tiihonen J, Wahlbeck K, Kiviniemi V. The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. Schizophr Res 2009; 109: 10-14
• 32 Premkumar TS, Pick J. Lamotrigine for schizophrenia. Cochrane Database Syst Rev 2006; CD005962
• 33 Behdani F, Hebrani P, Rezaei Ardani A et al. Effect of topiramate augmentation in chronic schizophrenia: a placebo-controlled trial. Arch Iran Med 2011; 14: 270-275
• 34 Afshar H, Roohafza H, Mousavi G et al. Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial. J Psychopharmacol 2008; 23: 157-162
• 35 Muscatello MR, Bruno A, Pandolfo G et al. Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. J Psychopharmacol 2010; 25: 667-674
• 36 Lucena Dde, Fernandes BS, Berk M et al. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. J Clin Psychiatry 2009; 70: 1416-1423
• 37 Singh SP, Singh V. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia. CNS Drugs 2011; 25: 859-885
• 38 Joshi I, Yang Y-M, Wang L-Y. Cellular/molecular coincident activation of metabotropic glutamate receptors and NMDA receptors (NMDARs) downregulates perisynaptic/extrasynaptic NMDARs and enhances high-fidelity neurotransmission at the developing calyx of the held synapse. J Neurosci 2007; 27: 9989-9999
• 39 Gordon JA. Testing the glutamate hypothesis of schizophrenia. Nat Neurosci 2010; 13: 2-4
• 40 Homayoun H, Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 2007; 27: 11496-11500
• 41 Jackson M, Homayoun H, Moghaddam B. NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex. Proc Natl Acad Sic USA 2004; 101: 6391-6396